Dr. Kanhaiya Singh ia an Associate Professor at the McGowan Institute for Regenrerative Medicine, University of Pittsburgh. Dr. Singh received his doctoral degree in Biotechnology from Banaras Hindu University, India. Prior to joining the University of Pittsburgh, Dr. Singh served as an Assistant Professor of Surgery at the Indiana University. He completed his post-doctoral research at The Ohio State University.

Dr. Singh’s area of expertise is on epigenetics of diabetic vasculopathy and wound healing. His laboratory is investigating epigenetic mechanisms such as DNA methylation as a proxy for abnormal gene–environmental interactions in diabetic ischemic wounds. The lab’s current line of study aims to develop a simple and point-of-care approach to achieve targeted epigenetic editing of adult diabetic ischemic tissue in vivo. The research is funded through reseach grants from the NIH, U.S. Department of Defense, and the Commonwealth of Pennsylvania.

His laboratory is also investigating the molecular mechanism in diabetic vasculopathy and limb ischemia. Single-cell RNA sequencing and multiomic technologies are being applied to study the endothelial cells of the human diabetic skin in order to identify novel ligands and receptors that can improve outcomes of the vascular endothelial growth factor (VEGF) therapy. To that end, his team is employing tissue nanotransfection (TNT) technology as a delivery platform to administer combination gene therapy for diabetic ischemic limb rescue.

Dr. Singh serves as an editorial board member for Scientific Reports, an associate editor of Heliyon and Frontiers in Endocrinology, an academic editor for PLOS ONE and Genetics Research.